Side-effects

The most important side-effect of delavirdine is a skin rash that appears in 18 to 30% of people soon after starting the drug.1 The rash is occasionally accompanied by fever and lesions on the lips, mouth and genitals, lasting about three weeks. The rash is not usually severe and most people can continue the treatment. In clinical trials, approximately 5% of volunteers stopped delavirdine due to rash. Other side-effects include mild-to-moderate headache, fatigue, nausea, diarrhoea, and reversible liver abnormalities.

References

  1. Davey RT et al. Randomized, controlled phase I / II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type-1 infected patients. Antimicrob Agents Chemother 40: 1657-1664, 1996
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.